Yahoo Finance Eupraxia Pharmaceuticals Inc. (TSE:EPRX) insiders placed bullish bets worth CA$1.5m in the last 12 months
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) instance, it's good news for shareholders.
Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.
See our latest analysis for Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Insider Transactions Over The Last Year
The Independent Director John Montalbano made the biggest insider purchase in the last 12 months. That single transaction was for CA$427k worth of shares at a price of CA$1.75 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of CA$3.65. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Eupraxia Pharmaceuticals insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Eupraxia Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Eupraxia Pharmaceuticals
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Eupraxia Pharmaceuticals insiders own about CA$11m worth of shares (which is 14% of the company). Whilst better than nothing, we're not overly impressed by these holdings.
So What Does This Data Suggest About Eupraxia Pharmaceuticals Insiders?
The fact that there have been no Eupraxia Pharmaceuticals insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in Eupraxia Pharmaceuticals and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 4 warning signs for Eupraxia Pharmaceuticals you should be aware of, and 3 of them shouldn't be ignored.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
